Clinical Trial Update: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for apalutamide (JNJ-56021927) in high-risk prostate cancer patients receiving primary radiation therapy (ATLAS); the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING